louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06742437: Efficacy and Safety of a New Sperm Capacitation Method
Official title: Efficacy and Safety of a New Sperm Capacitation Method: a Prospective in Vitro Study on Semen Samples
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Reproductive Issues
Male Infertility
Asthenozoospermia
Oligozoospermia
Teratozoospermia
Lead sponsor: Fecundis Lab SL
Sponsor class: OTHER
First posted: 2024-12-19
Enrollment: 300
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Men attending fertility clinics who provide a semen sample with normal parameters (normozoospermia), or present a male factor (asthenozoospermia, oligozoospermia, teratozoospermia, or a combination thereof).

Brief summary: Prospective, multicenter research study with a split-sample design on semen samples, without intervention, to evaluate the efficacy and safety of HyperSperm, a new sperm capacitation method, in 300 semen samples with various characteristics and abnormalities, in an in vitro study over 12 months.


Eligibility criteria: Inclusion Criteria:

* Ability to provide a semen sample via masturbation

Exclusion Criteria:

* Current diagnosis of a sexually transmitted infection (STI)
* Previous diagnosis of hepatitis A, B, C, D, or HIV
* Prior participation in this study
* Participation in a clinical trial involving an intervention within the last 3 months

Primary outcomes:
measure: Hyperactivation
timeFrame: 2 hours
Secondary outcomes:
measure: Sperm vitality
timeFrame: 2 hours
measure: DNA fragmentation
timeFrame: 2 hours
measure: Sperm motility
timeFrame: 2 hours
measure: Survival
timeFrame: 20 hours
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Eugin Barcelona
city: Barcelona
country: Spain
facility: Fertty
city: Barcelona
country: Spain
facility: CIRH
city: Barcelona
country: Spain
facility: Natuvitro
Study officials:
affiliation: Fertty
name: Mariona Rius Mas, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01584037: Adenovirus Vaccine Pregnancy Registry
Official title: Adenovirus Vaccine Pregnancy Registry
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Adenovirus
Keywords: Adenovirus
Adenovirus Type 4
Adenovirus Type 7
Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
Collaborators: name: United States Department of Defense
First posted: 2012-04-24
Enrollment: 0
Sex: FEMALE
Minimum age (years): 17
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will consist of:

1. Women previously or currently enrolled in the U.S. Military who received Adenovirus Type 4 and Type 7 Vaccine, Live, Oral while pregnant or who conceived within 6 weeks of vaccine administration, and
2. Infants born to females with confirmed exposure to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, followed through one year post delivery.

Brief summary: The primary purpose of the Adenovirus Vaccine Pregnancy Registry is to prospectively collect data concerning:

1. Pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral,
2. Potential confounding factors, and
3. The outcome of these pregnancies.

The secondary purpose of the Adenovirus Vaccine Pregnancy Registry is to evaluate the frequency of birth defects in prospectively enrolled pregnant women. This Registry is also designed to detect any unusual patterns of birth defects.


Eligibility criteria: Inclusion Criteria:

For women:

* U.S. Military service member, present or former
* Confirmed exposure to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
* Received Adenovirus Type 4 and Type 7 Vaccine, Live, Oral while pregnant or has an estimated date of conception (DOC) within 6 weeks after receiving Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
* Positive β-hCG test or fetal ultrasound,and
* Verbal and/or written informed consent obtained from the patient.

For live born offspring:

* Infant born to a woman meeting the above inclusion criteria and enrolled in the Registry, followed through one year post delivery, and
* Verbal and/or written informed consent obtained from the mother of the infant.

Exclusion Criteria:

* Patients who refuse to provide informed consent (verbal or written) to the Institutional Review Board (IRB)-approved informed consent.
* Females not exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral within the inclusion criteria period.
* Patients not willing to meet Registry study conditions and requirements.

Primary outcomes:
measure: Adverse Pregnancy Outcome by observation
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Wilmington
country: United States
facility: INC Research, LLC (Registry Coordinating Center)
state: North Carolina
Study officials:
affiliation: Syneos Health
name: Vikki Brown, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06778837: Lymphedema Sensor Technology Development Study
Official title: Validation of Wearable Sensors to Monitor Tissue Hydration and Stiffness in Patients with Lymphedema
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lymphedema Arm
Lymphedema
Cancer
Keywords: Sensor
Device
Lymphedema
Upper Extremity
Wearable
Tissue
Hydration
Stiffness
Cancer
Lead sponsor: Northwestern University
Sponsor class: OTHER
Collaborators: name: Robert H. Lurie Cancer Center
First posted: 2025-01-16
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will recruit patients using the above specified criteria in the Chicagoland area.

Brief summary: The goal of this clinical trial in adult patients diagnosed with upper extremity lymphedema is to test the safety and effectiveness of small, wearable sensors that may be able to measure lymphedema. The main questions this study aims to answer are:

* Do these sensors detect lymphedema?
* If so, how accurate are these wearable sensors?

Participants will complete one in-person measurement session and one phone call with study staff 14 days after the measurement session to check-in on the participant's well-being.


Eligibility criteria: Inclusion Criteria:

* Patients with a diagnosis of unilateral lymphedema that affects the upper extremity (UE).
* Patients previously diagnosed with non-metastatic cancer.
* Adults 18 years of age and older.

Exclusion Criteria:

* Patients with history of lymphatic surgery.
* Patients with implantable devices (e.g., pacemaker, pacemaker/defibrillator, intrathecal pump, joint replacements, etc.) or any other device deemed unsafe by the treating investigator.
* Patients with an amputation involving the upper extremity.
* Patients with known allergies to adhesives - including silicone adhesives.
* Patients with the following comorbidities: diabetes, congestive heart failure, peripheral vascular disease, irradiated upper extremity skin, psoriasis, atopic dermatitis, open wounds/skin breakdown.

Primary outcomes:
measure: Tissue Hydration Score Recorded from the Tissue Hydration Sensor
timeFrame: From enrollment to the end of the measurement session (appx. 3 hours)
measure: Tissue Stiffness Score from the Tissue Stiffness Sensor
timeFrame: From enrollment to the end of the measurement session (appx. 3 hours)
Secondary outcomes:
measure: Bioimpedance spectroscopy (BIS) L-Dex score
timeFrame: Three hours
measure: Tissue Dielectric Constant (TDC)
timeFrame: From enrollment to the end of the measurement session (appx. 3 hours)
measure: Volume of the Upper Extremities
timeFrame: Three hours
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
Study officials:
References:
Clinical trial NCT00492037: Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia
Official title: A 5-Day, Double-Blind, Placebo-Controlled Multicenter Study of Oral YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hyponatremia
Keywords: hyponatremia
hypervolemic
euvolemic
conivaptan
Lead sponsor: Cumberland Pharmaceuticals
Sponsor class: INDUSTRY
Collaborators: name: Parke-Davis
First posted: 2007-06-27
Enrollment: 83
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study of efficacy \& safety of oral YM087 in subjects with euvolemic or hypervolemic hyponatremia


Eligibility criteria: Inclusion Criteria:

* Serum Sodium 115 to \<130mEq/L
* Plasma Osmolarity \<290 mOsmol/kg H2O

Exclusion Criteria:

* Significant renal insufficiency
* Serum sodium increase of ≥8 mEq/L over the baseline day ( Hours 0 to 12)

Primary outcomes:
measure: Change in serum sodium from Baseline Safety of each dosing regimen
timeFrame: Beginning through end of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Bruxelles
country: Belgium
city: Liege
country: Belgium
city: Tournai
country: Belgium
city: Jyväskylä
country: Finland
city: Turku
country: Finland
city: Garches
country: France
city: Limoges
country: France
city: Paris Cedex 10
country: France
city: Bad Nauheim
country: Germany
city: Berlin
country: Germany
city: Dresdan
country: Germany
city: Göttingen
country: Germany
city: Munchen
country: Germany
city: Ferrara
country: Italy
city: Pavia
country: Italy
city: Pisa
country: Italy
city: Verona
country: Italy
city: Delft
country: Netherlands
city: Groningen
country: Netherlands
city: Leiden
country: Netherlands
city: Nijmegen
country: Netherlands
city: Radomsko
country: Poland
city: Warsaw
country: Poland
city: Wroclaw
country: Poland
city: Barcelona
country: Spain
city: Cordoba
country: Spain
city: Madrid
country: Spain
city: Cardiff
country: United Kingdom
city: Manchester
country: United Kingdom
Study officials:
affiliation: Cumberland Pharmaceuticals, Inc.
name: Art Wheeler, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06659237: Fecal and Oral Microbiota Between Pancreatic Cancer and Benign/Low-grade Malignant Tumor Patients
Official title: Fecal and Oral Microbiota Between Pancreatic Cancer and Benign/Low-grade Malignant Tumor Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Microbiome
Pancreatic Neoplasms
16s RRNA
Keywords: fecal microbiome
oral microbiome
pancreatic neoplasms
16s rRNA
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2024-10-26
Enrollment: 121
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a pancreatic tumor detected via imaging

Brief summary: Significant gaps exist in understanding the gastrointestinal microbiota in patients with pancreatic cancer (PCA) versus benign or low-grade malignant pancreatic tumors (NPCA). This study aimed to analyze these microbiota characteristics and explore their potential use in distinguishing malignant pancreatic lesions.

Detailed description: In the past decade, microbiome research has rapidly progressed, revealing the critical roles of fecal and oral microbiota in maintaining internal homeostasis. Studies employing 16S rRNA and metagenomics have highlighted dysbiosis of the fecal and oral microbiota as closely linked to PCA development and progression. However, significant gaps exist in understanding the fecal and oral microbiota in patients with pancreatic cancer (PCA) versus benign or low-grade malignant pancreatic tumors (NPCA). This study aimed to analyze fecal and oral microbiota characteristics, and to establish classifiers to discriminate PCA from NPCA, providing a reference for early clinical identification of malignant tumors.

Eligibility criteria: Inclusion Criteria:

* Patients with a pancreatic tumor detected via imaging with no prior treatment before sample collection
* Patients volunteer to provide oral and fecal samples

Exclusion Criteria:

* Current or previous diagnoses of (a) other malignancies, (b) infectious diseases, (c) oral or gastrointestinal disorders (d) psychiatric or neurodegenerative disorders
* Specific medical procedures or interventions within defined periods, including (a) antibiotic, hormone therapy, or immunosuppressant within the past three months, (b) gastrointestinal reconstructive surgery within the past three months, (c) frequent use of cathartics, antidiarrheals, or therapeutic doses of probiotics within the past month, (d) oral or gastrointestinal examinations within the past three days

Primary outcomes:
measure: the accuracy of the diagnostic classifier
timeFrame: From enrollment to the end of treatment at 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Department of General Surgery, Peking Union Medical College Hospital (PUMCH)
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital
name: Menghua Dai, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00329537: Study of Sargramostim in Moderately to Severely Active Crohn's Disease
Official title: Open-Label Phase 1 Study to Assess the Tolerability, Pharmacokinetics and Safety of 2 and 6 µg/kg Sargramostim (SH L 04023) Administered Subcutaneously Once Daily for 4 Weeks, and Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess the Efficacy and Safety of 6 µg/kg Sargramostim (SH L 04023) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease (Sargramostim Phase 1/2 Study)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Crohn's Disease
Keywords: Crohn's Disease
Sargramostim
CDAI
Moderately to severely active Crohn's Disease
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2006-05-24
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the tolerability, pharmacokinetics and safety of 2 and 6 micro g/kg/day sargramostim administered subcutaneously once daily for 4 weeks, and to assess the efficacy and safety of 6 micro g/kg/day sargramostim administered subcutaneously once daily for 8 weeks in comparison with placebo, in patients with moderately to severely active Crohn's disease.

Detailed description: On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc.

Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of Crohn's disease (endoscopic or radiological evaluation) at least 4 months prior to receiving the first dose of study drug
* Moderately to severely active Crohn's disease at time of screening (i.e., Crohn's disease activity index \[CDAI\] \>220 and \<475 points)

Exclusion Criteria:

* Colostomy or ileostomy
* Immediate need for gastrointestinal (GI) surgery for active GI bleeding, peritonitis, intestinal obstruction, or intra-abdominal or perianal abscess requiring surgical drainage
* GI surgery within 6 months prior to receiving the 1st dose of study drug
* Symptoms of bowel obstruction or confirmed evidence of a clinically-significant stricture within the last 6 months that has not been surgically corrected

Primary outcomes:
measure: CDAI [Crohn's Disease Active Index] improvements
timeFrame: Baseline, 1w, 2w, 4w, 6w, 8w, 10w, 12w
Secondary outcomes:
measure: PRO [Patient-reported outcome] variables (QOL [Quality of life]
timeFrame: Baseline, 1w, 4w, 8w, 12w
measure: PGI-C [Patient global impression of change])
timeFrame: Baseline, 1w, 2w, 4w, 6w, 8w, 10w, 12w
Other outcomes:
Locations:
Study officials:
affiliation: Genzyme, a Sanofi Company
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT03493737: Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma
Official title: Cost-Utility Evaluation Comparing Hospital Versus Home-Based Bortezomib in Multiple Myeloma: The ADHOMY Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Myeloma
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2018-04-10
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with multiple myeloma requiring a treatment with Bortezomib

Brief summary: Bortezomib needs repetitive visits at hospital for injections. Hospital-at-Home (HaH) might be an attractive and suitable alternative in this situation.

This study aim to perform a cost-utility analysis of two different strategies in several HaH structures within the Grand Est region in France.

Detailed description: Bortezomib is a standard therapy of newly-diagnosed multiple myeloma and is also approved for relapsing disease, requiring the patients to travel to the outpatient-hospital (OH) once a week for several months. Hospital-at-Home (HaH) might be an attractive and suitable alternative in this situation.

This study aim to perform a cost-utility analysis of two different strategies in several HaH structures within the Grand Est region in France: exclusive hospital-based Bortezomib administration versus combined administration in both OH and HaH.

Eligibility criteria: Inclusion Criteria:

* Minimum age 18
* Enrolled in a social security scheme
* Diagnosis of multiple myeloma in first line or relapse
* Treatment plan including Bortezomib, adopted in a multidisciplinary meeting in a department of Hematology in Nancy (main investigator), Reims, Strasbourg University Hospitals or Metz-Thionville and Mulhouse local state-run hospitals
* The patients must have agreed to the treatment protocol and to take IV or PO associated drugs prescribed in addition to Bortezomib
* The patients must meet the 2003 eligibility criteria of the National Agency for Accreditation and Evaluation in Health (ANAES) for chemotherapy at home:

  * Absence of severe adaptive or psychological disorders, ability to understand the protocol
  * Absence of cognitive impairment
  * Availability and agreement of the attending physician
  * Home safety and hygiene
* Do not decline to participate in the research and share their personal data

Exclusion Criteria:

* Already participating in another trial
* Have a follow-up and/or treatment for another condition requiring a particular care during the Bortezomib treatment period

Primary outcomes:
measure: Cost therapy assessment
timeFrame: 10 months follow-up per patient
measure: EQ-5D questionnaire
timeFrame: 10 months follow-up per patient
measure: QLQ-C30 questionnaire
timeFrame: 10 months follow-up per patient
Secondary outcomes:
Other outcomes:
Locations:
city: Vandœuvre-lès-Nancy
country: France
facility: CHRU Nancy
Study officials:
References:
Clinical trial NCT01369537: Neurological Impact of Vascular Events In Noncardiac Surgery patIents cOhort evaluatioN Pilot Study
Official title: Neurological Impact of Vascular Events In Noncardiac Surgery patIents cOhort evaluatioN Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Perioperative Stroke
Lead sponsor: McMaster University
Sponsor class: OTHER
First posted: 2011-06-09
Enrollment: 100
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients aged 65 years and older undergoing noncardiac surgery and staying in hospital overnight.

Brief summary: Two hundred million adults worldwide have major surgery every year. A million of these patients will have an obvious stroke after their surgery. Another 10 million patients may have "silent" strokes. Although silent strokes are not diagnosed immediately, they are likely to reduce patients' short-term memory, concentration, and ability to function at home. However, the investigators do not know how common silent strokes are after noncardiac surgery, nor the extent to which they affect brain function.

The investigators will first perform a pilot trial to determine the feasibility of the larger study that will provide the definitive answer to this question. Participating patients will be assessed by questionnaire before and after surgery, and will have a magnetic resonance imaging (MRI) study of the brain after the surgery to look for silent strokes. Combining the results of the MRI and the questionnaires will allow us to determine the frequency of silent strokes after non-cardiac surgery, and their effect on brain function. The NeuroVISION Pilot Study will determine the feasibility of a large study to examine the frequency and the impact of silent stroke in patients who undergo noncardiac surgery.


Eligibility criteria: Inclusion Criteria:

* age 65,
* undergoing noncardiac surgery,
* regional or general anesthetic.

Exclusion Criteria:

-Patients who have a contraindication to MRI.

Primary outcomes:
measure: Rate of recruitment
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: Juravinski Hospital
state: Ontario
Study officials:
affiliation: McMaster University
name: PJ Devereaux, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mrkobrada M, Hill MD, Chan MT, Sigamani A, Cowan D, Kurz A, Sessler DI, Jacka M, Graham M, Dasgupta M, Dunlop V, Emery DJ, Gulka I, Guyatt G, Heels-Ansdell D, Murkin J, Pettit S, Sahlas DJ, Sharma M, Sharma M, Srinathan S, St John P, Tsai S, Gelb AW, O'Donnell M, Siu D, Chiu PW, Sharath V, George A, Devereaux PJ. Covert stroke after non-cardiac surgery: a prospective cohort study. Br J Anaesth. 2016 Aug;117(2):191-7. doi: 10.1093/bja/aew179.
Clinical trial NCT04510337: Does Adding Magnesium Sulphate to Low Dose Rocuronium Affects Depth of Blockade
Official title: Does Adding Magnesium Sulphate to Low Dose Rocuronium Affects the Depth of Blockade in Cancer Patients Undergoing Direct Laryngoscope Surgical Procedures
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anesthesia
Lead sponsor: National Cancer Institute, Egypt
Sponsor class: OTHER
First posted: 2020-08-12
Enrollment: 60
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aim is to compare the effect of magnesium sulphate combined with low dose rocuronium versus standard dose rocuronium

Detailed description: Comparing the effect of magnesium sulphate combined to low dose rocuronium versus standard dose rocuronium in cancer patients undergoing direct laryngoscopy for laryngeal tumors regarding intubating conditions, intraoperative relaxation, depth of anesthesia and recovery time.

Eligibility criteria: Inclusion Criteria:

Patients with Laryngeal tumors

ASA I-II

Age 30-70 years

Exclusion Criteria:

Renal and or hepatic insufficiency

Neuromuscular disease

Large glottic and/or supra-glottic lesions with or without breathing difficulties

Known allergy to any of the used drug

Primary outcomes:
measure: Onset and duration of muscle relaxant
timeFrame: 90 minutes
Secondary outcomes:
measure: Degree of muscle relaxation
timeFrame: 90 minutes
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: National Cancer Institute
Study officials:
affiliation: Lecturer
name: Walaa Y Elsabeeny, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Lecturer
name: Mohamed A Wadod, MD
role: STUDY_DIRECTOR
References: